RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0042-1750716
Acute Liver Injury due to Glecaprevir/Pibrentasvir in a Patient with Chronic Hepatitis C Virus Infection without Cirrhosis
Funding None.
Abstract
We reported a rare case of acute liver injury in a patient with chronic hepatitis C virus infection without cirrhosis 4 weeks after initiation of glecaprevir/pibrentasvir. After prompt cessation of antiviral therapy, liver enzymes rapidly improved toward baseline. This case reflects the need to remain vigilant for the development of acute liver injury after initiation of glecaprevir/pibrentasvir even without a diagnosis of cirrhosis.
Note
Informed consent was obtained for this case report.
Authors' Contributions
A.J. and K.M. wrote the manuscript. K.M. is the article guarantor.
Publikationsverlauf
Artikel online veröffentlicht:
03. Juli 2022
© 2022. Avicenna Journal of Medicine. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Müllhaupt B, Semela D, Ruckstuhl L. et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. Swiss Med Wkly 2021; 151: w20399
- 2 FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease. U.S. Food and Drug Administration; 2019
- 3 Yoon JH, Kim SM, Kang G, Kim HJ, Jun CH, Choi SK. A case report of glecaprevir/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis. Medicine (Baltimore) 2019; 98 (39) e17343
- 4 Naranjo CA, Busto U, Sellers EM. et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30 (02) 239-245
- 5 Highlights of Prescribing Information. FDA. 2017 . Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208434s003lbl.pdf
- 6 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, Clinical Practice Guidelines Panel: Chair, EASL Governing Board representative, Panel members. EASL recommendations on treatment of hepatitis C: final update of the series☆. J Hepatol 2020; 73 (05) 1170-1218
- 7 Hammami MB, Aboushaar R, Alsabbagh E. Glecaprevir/pibrentasvir-associated acute liver injury in non-cirrhotic, chronic HCV infection without HBV co-infection. BMJ Case Rep 2019; 12 (05) e226622
- 8 Hara T, Ohara T, Taniguchi M. et al. Severe liver injury associated with glecaprevir plus pibrentasvir therapy in a patient with treatment-naïve hepatitis C virus infection. Intern Med 2021; 60 (15) 2437-2443
- 9 Mavyret, in LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012